Toru Takiguchi

Toru Takiguchi

Auto-generated profile, based on publicly available information

Toru Takiguchi

Department of Emergency and Critical Care Medicine, Nippon Medical School, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2022 in Critical Care
Verified
Journal Article
Open access
PDF file
AIAkihiko Inoue
Akihiko Inoue
THToru Hifumi
Toru Hifumi
TSTetsuya Sakamoto
Tetsuya Sakamoto
HOHiroshi Okamoto
Hiroshi Okamoto
JKJun Kunikata
Jun Kunikata
JSJunya Shimazaki
Junya Shimazaki
Background: The prevalence of extracorporeal cardiopulmonary resuscitation (ECPR) in patients with out-of-hospital cardiac arrest (OHCA) has been increasing rapidly worldwide. However, guidelines or clinical studies do not provide sufficient data on ECPR practice. The aim of this study was to provide real-world data on ECPR for patients with OHCA, including details of complications.Methods: We did a retrospective database analysis of observational multicenter cohort study in Japan. Adult patients with OHCA of presumed cardiac etiology who received ECPR between 2013 and 2018 were included. The primary outcome was favorable neurological outcome at hospital discharge, defined as a cerebral performance category of 1 or 2.Results: A total of 1644 patients with OHCA were included in this study. The patient age was 18–93 years (median: 60 years). Shockable rhythm in the initial cardiac rhythm at the scene was 69.4%. The median estimated low flow time was 55 min (interquartile range: 45–66 min). Favorable neurological outcome at hospital discharge was observed in 14.1% of patients, and the rate of survival to hospital discharge was 27.2%. The proportions of favorable neurological outcome at hospital discharge in terms of shockable rhythm, pulseless electrical activity, and asystole were 16.7%, 9.2%, and 3.9%, respectively. Complications were observed during ECPR in 32.7% of patients, and the most common complication was bleeding, with the rates of cannulation site bleeding and other types of hemorrhage at 16.4% and 8.5%, respectively.Conclusions: In this large cohort, data on the ECPR of 1644 patients with OHCA show that the proportion of favorable neurological outcomes at hospital discharge was 14.1%, survival rate at hospital discharge was 27.2%, and complications were observed during ECPR in 32.7%.

1 January 2021 in Acute Medicine & Surgery
Verified
Journal Article
Open access
PDF file
THToru Hifumi
Toru Hifumi
AIAkihiko Inoue
Akihiko Inoue
TTToru Takiguchi
Toru Takiguchi
KWKazuhiro Watanabe
Kazuhiro Watanabe
TOTakayuki Ogura
Takayuki Ogura
YKYasuhiro Kuroda
Yasuhiro Kuroda
Aim: A lack of known guidelines for the provision of extracorporeal cardiopulmonary resuscitation (ECPR) to patients with out‐of‐hospital cardiac arrest (OHCA) has led to variability in practice between hospitals even in the same country. Because variability in ECPR practice has not been completely examined, we aimed to describe the variability in ECPR practice in patients with OHCA from the emergency department (ED) to the intensive care units (ICU).Methods: An anonymous online questionnaire to examine variability in ECPR practice was completed in January 2020 by 36 medical institutions who participated in the SAVE‐J II study. Institutional demographics, inclusion and exclusion criteria, initial resuscitation management, extracorporeal membrane oxygenation (ECMO) initiation, initial ECMO management, intra‐aortic balloon pumping/endotracheal intubation/management during coronary angiography, and computed tomography criteria were recorded.Results: We received responses from all 36 institutions. Four institutions (11.1%) had a hybrid emergency room. Cardiovascular surgery was always involved throughout the entire ECMO process in only 14.7% of institutions; 60% of institutions had formal inclusion criteria and 50% had formal exclusion criteria. In two‐thirds of institutions, emergency physicians carried out cannulation. Catheterization room was the leading location of cannulation (48.6%) followed by ED (31.4%). The presence of formal exclusion criteria significantly increased with increasing ECPR volume (P for trend <0.001). Intra‐aortic balloon pumping was routinely initiated in only 25% of institutions. Computed tomography was routinely carried out before coronary angiography in 25% of institutions.Conclusions: We described the variability in ECPR practice in patients with OHCA from the ED to the ICU.

11 February 2020 in Critical Care Medicine
Verified
Journal Article
Closed access
TTToru Takiguchi
Toru Takiguchi
MNMikio Nakajima
Mikio Nakajima
HOHiroyuki Ohbe
Hiroyuki Ohbe
YSYusuke Sasabuchi
Yusuke Sasabuchi
HMHiroki Matsui
Hiroki Matsui
HYHideo Yasunaga
Hideo Yasunaga
Objectives: Previous studies have suggested that vasodilator therapy may be beneficial for patients with nonocclusive mesenteric ischemia. However, robust evidence supporting this contention is lacking. We examined the hypothesis that vasodilator therapy may be effective in patients diagnosed with nonocclusive mesenteric ischemia. Design: Retrospective cohort study. Setting: The Japanese Diagnosis Procedure Combination inpatient database. Patients: A total of 1,837 patients with nonocclusive mesenteric ischemia from July 2010 to March 2018. Interventions: None. Measurements and Main Results: We compared patients who received vasodilator therapy (vasodilator group; n = 161) and those who did not (control group; n = 1,676) using one-to-four propensity score matching. Vasodilator therapy was defined as papaverine and/or prostaglandin E1 administered via venous and/or arterial routes within 2 days of admission. Only patients who did not receive abdominal surgery within 2 days of admission were analyzed. The main outcomes were in-hospital mortality and abdominal surgery performed greater than or equal to 3 days after admission. After propensity score matching, in-hospital mortality was significantly lower in the vasodilator group (risk difference, –11.6%; p = 0.005). The proportion of patients who received abdominal surgery at greater than or equal to 3 days after admission was also significantly lower in the vasodilator group (risk difference, –10.2%; p = 0.002). Conclusions: Vasodilator therapy with papaverine and/or prostaglandin E1 is associated with lower in-hospital mortality and prevalence of abdominal surgery in patients with nonocclusive mesenteric ischemia.

1 March 2020 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
TNTakahito Nei
Takahito Nei
JHJun Hagiwara
Jun Hagiwara
TTToru Takiguchi
Toru Takiguchi
SYShoji Yokobori
Shoji Yokobori
KSKim Shiei
Kim Shiei
HKHaru Kato
Haru Kato

23 October 2023 in Chest
Verified
Journal Article
Closed access
TTToru Takiguchi
Toru Takiguchi
NTNaoki Tominaga
Naoki Tominaga
THTakuro Hamaguchi
Takuro Hamaguchi
TSTomohisa Seki
Tomohisa Seki
JNJun Nakata
Jun Nakata
HYHideto Yokoi
Hideto Yokoi

4 February 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
YNYuji Nishimoto
Yuji Nishimoto
HOHiroyuki Ohbe
Hiroyuki Ohbe
JNJun Nakata
Jun Nakata
TTToru Takiguchi
Toru Takiguchi
MNMikio Nakajima
Mikio Nakajima
HYHideo Yasunaga
Hideo Yasunaga
Background: It is unclear whether an intra‐aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with extracorporeal membrane oxygenation (ECMO) is better. Methods: Using the Japanese Diagnosis Procedure Combination database from September 2016 to March 2022, we identified inpatients who received an Impella or IABP in combination with ECMO (ECPella or ECMO+IABP group, respectively). The primary outcome was in‐hospital mortality, and the secondary outcomes included the length of hospital stay, length of ECMO, total hospitalization cost, complications, and durable mechanical circulatory support implantations. Propensity score matching was performed to compare the outcomes between the groups. Results: Of 14 319 eligible patients, 590 (4.1%) received ECPella and 13 729 (96%) received ECMO+IABP. The mean age of patients was 65 years, 77% were men, and 57% had acute coronary syndrome. After propensity score matching, the patient characteristics were well balanced between the groups. The 14‐day mortality rate was lower in the ECPella group than in the ECMO+IABP group (28.0% versus 36.8%; risk difference, −8.2% [95% CI, −13.8 to −2.7]), whereas there was no significant difference in in‐hospital mortality between the groups (58.3% versus 56.6%; risk difference, 2.4% [95% CI, −3.5 to 8.2]). The ECPella group had a higher total hospitalization cost, increased renal replacement therapy during hospitalization, and more durable mechanical circulatory support implantations than the ECMO+IABP group. Conclusions: This nationwide inpatient database study showed no significant difference in in‐hospital mortality between the groups, but ECPella was associated with a higher total hospitalization cost, increased renal replacement therapy during hospitalization, and more durable mechanical circulatory support implantations than ECMO+IABP.